CXCL12 and pancreatic neoplasm: For example, a recent publication demonstrates that targeting the CXCL12-CXCR4 axis with AMD3100 (Plerixafor) reverses FAP+ CAF-mediated immunosuppression and synergizes with anti-PD-L1 immunotherapy in pancreatic cancer [15].